As GLP-1 medications have become among the most widely prescribed drugs in modern medicine, an early shadow followed them — reports of depression and suicidal thoughts that prompted regulatory scrutiny. A systematic review of nearly five million patients now offers a more settled picture: across nine of ten cohort studies, these drugs carried no elevated psychiatric risk, and in some cases appeared to offer protection against self-harm. Yet one dissenting study, drawn from obesity clinics, recorded sharply higher rates of depression and anxiety — a reminder that in medicine, consensus and exce